News

Fierce Pharma1d
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...
Will Indians get blockbuster weight-loss drugs at cost of cheaper insulin?
Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
US patients lose access to cheaper weight-loss drugs as market for replicas winds down
Pharmacies told to stop making custom versions of Wegovy and Zepbound after shortages declared officially over ...
Novo Nordisk (NVO) Is a Good Short-Term Pick, Wealth Manager Says
Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the ...
24/7 Wall St.2d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Futurism on MSN4d
Novo Nordisk Is Getting Absolutely Destroyed
Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.